Amid current economic uncertainties, investing in defensive stocks appears as your best bet for stability, especially if a ...

Each of the RSU grants vests ratably in equal installments on the first, second, and third anniversaries of the grant date, subject to the recipient’s continued service with the Company ...

The Food and Drug Administration (FDA) recently expanded approval for Spravato, an antidepressant nasal spray used to treat depression. Parkside Psychiatric Hospital has a Spravato outpatient ...

Eldredge finally found relief. He said things immediately got better about six months ago when he tried Spravato. “It’s so life-changing,” said Eldredge. Spravato is a ketamine-derived nasal ...

Gregory Mattingly, MD, president, Midwest Research Group, founding partner, St. Charles Psychiatric Associates, discusses the immediate impact Spravato has had on patients with treatment-resistant ...

An estimated 21 million American adults suffer from clinical depression. © 2025 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes ...

Spravato (esketamine ... “Estimates of the costs of providing the clinical service for esketamine were highly uncertain, as are the costs of repeated courses of the drug,” he added.

Gregory Mattingly, MD, president, Midwest Research Group, founding partner, St. Charles Psychiatric Associates, discusses the approval of Spravato for treatment-resistant depression. PE: How does ...

The Food and Drug Administration (FDA) has expanded its approval of a ketamine-derived nasal spray, Spravato (esketamine), as a standalone therapy for adults with treatment-resistant depression.

The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of MDD in those who have not responded to at least two oral antidepressants. Hundreds of ...

"Spravato helps people who suffer from chronic depression feel better. In conjunction with another antidepressant, it has shown a high success rate. Parkside offers this service to reduce ...

Drug is the first and only approved monotherapy for refractory major depressive disorder. (HealthDay News) — The US Food and Drug Administration has approved Spravato (esketamine) CIII nasal ...